Symptom Checker Stay Updated Share Now FAQs/Glossary
Top line opener
Know iMCD Know iMCD
  • Understanding iMCD
    • About iMCD
    • iMCD Symptoms
  • Road to Diagnosis
    • Diagnostic Tests
    • What it looks like
  • Living With iMCD
    • Treatment Options
    • Lifestyle Tips
  • iMCD Voices
  • Resources
    • Community Support
    • For Caregivers
  • For HCPs
    • About iMCD
    • Diagnosing iMCD
    • Treating iMCD
Menu opener

Treating patients with iMCD

  • About iMCD
  • Diagnosing iMCD
  • Treating iMCD
decor-left-1 decor-right-1

Importance to Treat

Even after it’s diagnosed, iMCD often leads to hospitalization

60% of patients were hospitalized the first year after iMCD diagnosis
  • Idiopathic multicentric Castleman disease (iMCD) is a progressive disease with a poor prognosis2,3
  • Regardless of severity of clinical presentation, high rates of hospitalizations and ED visits are observed in patients with iMCD2

aRetrospective database claims analysis that assessed hospitalizations, ED visits, iMCD-related comorbidities, and organ failure in US patients with Castleman disease (over 30 million) between January 1, 2017, and December 31, 2019. Minor criteria from the Castleman Disease Collaborative Network (CDCN) diagnostic criteria were applied to ensure that the patients had iMCD.1,3

Despite diagnosis, most patients with iMCD are undertreated4

More than 70% of patients receive steroid monotherapy
decor-left-1 decor-right-1

Treating patients with iMCD

There are various therapies being used in the treatment of patients with iMCD. The CDCN, the same group that published the first consensus diagnostic criteria, has developed formal guidelines for the treatment of iMCD.5

icon time

Timely
Diagnosis

Timely diagnosis and appropriate treatment can help bring the symptoms of iMCD under control.3

icon arrows

Ongoing
Treatment

Considering the chronic and progressive nature of iMCD, patients will need to receive ongoing treatment to keep their symptoms under control.5,6

icon shield and arrow

Following Treatment Guidelines

Evidence-based treatment guidelines have been developed to help healthcare professionals treat their patients with iMCD.5

star icon

Learn more about an iMCD treatment that may be right for your patient

    LEARN MORE    
decor-left-1 decor-right-1

Different journeys. Same fighting spirit.

Hear from the people who have been fighting iMCD for years, and learn how they have dealt with some of the challenges they have experienced.

Jessica

In 2005, Jessica began experiencing fever, night sweats, and swollen lymph nodes. After 14 long years, she found out that she has iMCD. Watch her story to learn about her journey to diagnosis.

Share Now

Carl

In 1985, there weren’t any guidelines to diagnose iMCD. But that didn’t stop Carl from getting an accurate diagnosis for his rare disease. Watch his journey to learn about the path he took to finally get diagnosed with iMCD.

Share Now

Frank & Dina

iMCD has troubled Frank for years. But with his wife Dina by his side, he was never going to back down. Watch the video to learn about the ups and downs they faced during their journey to diagnosis.

Share Now
decor-left-1 decor-right-1
image description

Sign up for more on iMCD

"*" indicates required fields

*Required.

By checking the adjacent box, you agree to allow EUSA Pharma to collect the information provided and to be contacted by EUSA Pharma in the future regarding its IL-6 neutralizing products and related disease education.

By submitting this form, you agree to allow EUSA Pharma to collect the information provided and to be contacted directly by a EUSA Pharma sales representative. Your information will not be used for any other purpose than for a representative to respond to your information request, or for us to send you other EUSA Pharma updates if you have registered to receive them.

EUSA Pharma will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of EUSA Pharma. EUSA Pharma will only use your information in accordance with its Privacy Policy.

References:
  1. Mukherjee S, Martin R, Sande B, et al. A longitudinal population level analysis of healthcare resource utilization, comorbidity, and survival in idiopathic multicentric Castleman disease patients. Presented at: 62nd American Society of Hematology (ASH) Annual Meeting and Exposition; December 5-8, 2020; virtual meeting.

  2. Mukherjee S, Martin R, Sande B, et al. A longitudinal population level analysis of healthcare resource utilization, comorbidity, and survival in idiopathic multicentric Castleman disease patients. Blood. 2020;136(suppl 1):11.

  3. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-1657.

  4. Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022;6(2):359-367.

  5. van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115 -2124.

  6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 29, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Are you a US healthcare professional?

If so, you will be directed to the website that contains information intended for US healthcare professionals.

Yes No
I am outside the United States >
Check your SYMPTOMS

© 2022 EUSA Pharma (US) LLC. All rights reserved. This site is intended for US residents only.

Third-party trademarks used herein are trademarks of their respective owners. This site is not intended to provide medical advice. Please see your physician. The Symptom Checker is not intended for use in the diagnosis of iMCD.

  • Privacy Policy
  • Cookie Policy
  • Terms of Use
EUSA Pharma
  • July 2022
  • US-NPS-2200064

Your iMCD Diary

Save and use this Patient Diary online with your Google account by selecting “Google Sheet” and then “Use Template,” or download to your computer by selecting “Excel File.”

Google Sheet Excel File

No data is stored by or transferred to this KnowiMCD.com website. This site contains links to other websites, and these links will direct users to third-party sites.

Loading...

Please wait a moment.

Are you located in the United States?

If so, you will be directed to the website that contains information intended for a US audience.

Yes No

Viral hemophagocytic lymphohistiocytosis.

A doctor who specializes in the branch of medicine that deals with rheumatic conditions.

Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.

Positron emission tomography (PET) is a method of producing a 3-dimensional image of the internal structures of body tissues after administering a natural biochemical substance like glucose or fatty acids. These images are generated with the help of a computer.

A doctor who evaluates the changes caused by disease in tissues and body fluids and helps reach a diagnosis.

A doctor who specializes in the diagnosis and treatment of kidney abnormalities.

Macrophage activation syndrome.

Malignancy-associated hemophagocytic lymphohistiocytosis.

A disease in which cells of the lymph system grow excessively

Lymph nodes make immune cells that help the body fight infection.

A key signaling molecule that helps to regulate the body’s immune system.

Infectious disease medicine is the subspecialty of internal medicine that focuses on diagnosing and managing infections.

A rare condition that affects multiple groups of lymph nodes throughout the body. Patients with iMCD are HIV negative and HHV-8 negative.

The underlying cause or origin of a disease is unknown.

Hemophagocytic lymphohistiocytosis.

Human immunodeficiency virus.

Human herpesvirus-8.

A doctor who specializes in the branch of medical science that deals with cancers of the blood and blood-forming tissues.

Powerful molecules that are normally secreted by the cells of the immune system in response to infectious or noninfectious agents.

An overreaction of the body’s immune system in which too many cytokines are released into the bloodstream very quickly, with potentially severe or life-threatening effects.

Computed tomography (CT) is a method of producing an image of the internal structures by passing an x‑ray through the body.

The removal and examination of tissue, cells, or fluids from the body.

A condition in which the body’s immune system accidentally attacks itself.

Autoimmune lymphoproliferative syndrome.

You are now leaving KnowiMCD.com.

Please click “OK” to continue or “CANCEL” to return to KnowiMCD.com

OK

By using the share feature, you agree that EUSA Pharma (US) LLC is not responsible for the content that you share on your personal social media account(s). When using social media share features, you agree to follow our Social Media Community Guidelines and acknowledge that you are sharing this on your selected personal social media accounts(s). Your use of this website will be overseen by the EUSA Pharma (US) LLC Privacy Policy.

Agree